Page 130 - Read Online

Page 20 of 25 Luo et al. Microbiome Res Rep 2025;4:10 https://dx.doi.org/10.20517/mrr.2024.57

PubMed PMC
39. Hanson ML, Hixon JA, Li W, et al. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology
2014;146:210-21.e13. DOI PubMed PMC
40. Zhou J, Li M, Chen Q, et al. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease
treatment after effective oral delivery. Nat Commun 2022;13:3432. DOI PubMed PMC
41. Chen H, Lei P, Ji H, et al. Escherichia coli Nissle 1917 ghosts alleviate inflammatory bowel disease in zebrafish. Life Sci
2023;329:121956. DOI
42. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012;490:55-60. DOI
PubMed
43. Zhou W, Sailani MR, Contrepois K, et al. Longitudinal multi-omics of host-microbe dynamics in prediabetes. Nature 2019;569:663-
71. DOI PubMed PMC
44. Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut 2014;63:1513-21. DOI PubMed
45. Rittiphairoj T, Pongpirul K, Janchot K, Mueller NT, Li T. Probiotics contribute to glycemic control in patients with type 2 diabetes
mellitus: a systematic review and meta-analysis. Adv Nutr 2021;12:722-34. DOI PubMed PMC
46. Wang Y, Dilidaxi D, Wu Y, Sailike J, Sun X, Nabi XH. Composite probiotics alleviate type 2 diabetes by regulating intestinal
microbiota and inducing GLP-1 secretion in db/db mice. Biomed Pharmacother 2020;125:109914. DOI PubMed
47. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994;107:1848-55. DOI PubMed
48. Sandoval DA, D’Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev
2015;95:513-48. DOI PubMed
49. Grandl G, Novikoff A, Dimarchi R, Tschöp MH, Müller TD. Gut peptide agonism in the treatment of obesity and diabetes. Compr
Physiol 2019;10:99-124. DOI PubMed
50. Agarwal P, Khatri P, Billack B, Low WK, Shao J. Oral delivery of glucagon like peptide-1 by a recombinant Lactococcus lactis.
Pharm Res 2014;31:3404-14. DOI PubMed
51. Luo J, Zhang H, Lu J, Ma C, Chen T. Antidiabetic effect of an engineered bacterium Lactobacillus plantarum-pMG36e -GLP-1 in
monkey model. Synth Syst Biotechnol 2021;6:272-82. DOI PubMed PMC
52. Wang L, Chen T, Wang H, et al. Engineered bacteria of MG1363-pMG36e-GLP-1 attenuated obesity-induced by high fat diet in
mice. Front Cell Infect Microbiol 2021;11:595575. DOI PubMed PMC
53. Takiishi T, Korf H, Van Belle TL, et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using
genetically modified Lactococcus lactis in mice. J Clin Invest 2012;122:1717-25. DOI PubMed PMC
54. Chavkin TA, Pham LD, Kostic A. E. coli Nissle 1917 modulates host glucose metabolism without directly acting on glucose. Sci Rep
2021;11:23230. DOI PubMed PMC
55. Bazi Z, Jalili M, Hekmatdoost A. The long term oral regulation of blood glucose in diabetic patients by using of Escherichia coli
Nissle 1917 expressing CTB-IGF-1 hybrid protein. Med Hypotheses 2013;81:961-2. DOI PubMed
56. Tu P, Ma Z, Wang H, et al. Expression of CTB-10×rolGLP-1 in E. coli and its therapeutic effect on type 2 diabetes. Curr Pharm
Biotechnol 2015;16:564-72. DOI PubMed
57. Qin Q, Chen Y, Li Y, et al. Intestinal microbiota play an important role in the treatment of type I diabetes in mice with BefA protein.
Front Cell Infect Microbiol 2021;11:719542. DOI PubMed PMC
58. Wang H, Wei J, Hu H, et al. Oral administration of bacterial β cell expansion factor A (BefA) alleviates diabetes in mice with type 1
and type 2 diabetes. Oxid Med Cell Longev 2022;2022:9206039. DOI PubMed PMC
59. Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U. Diagnosis, classification, and genetics of phenylketonuria and
tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab 2011;104 Suppl:S2-9. DOI PubMed
60. Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM. Phenylketonuria. Nat Rev Dis Primers 2021;7:36. DOI PubMed
PMC
61. Lichter-Konecki U, Vockley J. Phenylketonuria: current treatments and future developments. Drugs 2019;79:495-500. DOI PubMed
62. van Spronsen FJ, van Wegberg AM, Ahring K, et al. Key European guidelines for the diagnosis and management of patients with
phenylketonuria. Lancet Diabetes Endocrinol 2017;5:743-56. DOI
63. Martinez M, Harding CO, Schwank G, Thöny B. State-of-the-art 2023 on gene therapy for phenylketonuria. J Inherit Metab Dis
2024;47:80-92. DOI PubMed PMC
64. Kim W, Erlandsen H, Surendran S, et al. Trends in enzyme therapy for phenylketonuria. Mol Ther 2004;10:220-4. DOI
65. Levy HL, Sarkissian CN, Scriver CR. Phenylalanine ammonia lyase (PAL): from discovery to enzyme substitution therapy for
phenylketonuria. Mol Genet Metab 2018;124:223-9. DOI
66. Durrer KE, Allen MS, Hunt von Herbing I. Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment
of a novel treatment in vitro and in the PAHenu2 mouse model of PKU. PLoS One 2017;12:e0176286. DOI PubMed PMC
67. Ramírez AM, Rodriguez-López A, Ardila A, et al. Production of human recombinant phenylalanine hydroxylase in Lactobacillus
plantarum for gastrointestinal delivery. Eur J Pharm Sci 2017;109:48-55. DOI
68. Phumkhachorn P, Rattanachaikunsopon P. A broad host range food-grade cloning vector for lactic acid bacteria. Biologia
2016;71:457-63. DOI
69. Kaur T, Balgir PP, Kaur B. Correction to: construction of a shuttle expression vector for lactic acid bacteria. J Genet Eng Biotechnol
2020;18:38. DOI PubMed PMC